Dietary Intervention with Brown Top Millet Starch Ameliorates Dyslipidaemia and Gut Leakiness in High Fat Diet Fed Models

A high-fat diet (HFD) is well known to cause weight gain, blood sugar problems, abnormal cholesterol levels, and damage to the lining of the gut — the intestinal barrier that normally keeps harmful bacterial products out of the bloodstream. This study tested whether starch extracted from brown top millet (Browntop millet, Brachiaria ramosa), a traditional Indian grain, could reverse these effects in rats. The researchers isolated the starch, then created a chemically modified version with greater resistance to digestive enzymes, meaning it behaves more like dietary fibre and reaches the colon largely intact. Rats were fed a high-fat diet for eight weeks to induce metabolic syndrome, then switched to diets where the main carbohydrate was replaced with either the unprocessed or the modified millet starch for a further four weeks. The modified starch was the clear winner: it improved blood sugar control, normalised cholesterol and triglyceride levels, raised beneficial short-chain fatty acids, and restored key gut-barrier proteins (ZO-1 and occludin) while lowering a blood marker of gut leakiness (LBP). The unprocessed starch produced only modest, late-appearing benefits. The findings suggest that a simple dietary swap — replacing refined carbohydrates with modified resistant starch from brown top millet — could be a practical, non-drug strategy to combat the metabolic and gut-barrier damage caused by a Western-style high-fat diet.

• HFD significantly elevated fasting glucose and impaired glucose tolerance (Diet×Days interaction F(10,72)=28.1, P<0.001); modified BTMS (MHFD group) restored both fasting and post-load glycaemia across all measured time-points, whereas unprocessed starch (HFDP) showed benefit only at later GTT time-points.
• HFD increased plasma triglycerides, total cholesterol, and LDL while decreasing HDL (all P<0.001); modified BTMS normalised all four lipid parameters, and unprocessed BTMS produced only partial improvement.
• HFD reduced circulating short-chain fatty acids and elevated glycerol, free fatty acids, and β-hydroxybutyrate (all P<0.001), indicating metabolic inflexibility and increased fat catabolism; modified BTMS reversed all five metabolite changes, consistent with enhanced colonic fermentation of resistant starch.
• HFD increased serum lipopolysaccharide-binding protein (LBP) and decreased ileal tight-junction proteins ZO-1 and occludin (all P<0.001), confirming gut barrier disruption; modified BTMS significantly reduced LBP and restored ZO-1 and occludin toward normal-diet levels.
• The modified BTMS was characterised as containing 11.6 ± 0.8% resistant starch (assessed by pancreatic α-amylase/amyloglucosidase digestion + GOPOD colorimetry), indicating partial but meaningful enzymatic resistance compared with the unprocessed isolate.

Adult male Sprague–Dawley rats (n=30) were fed either a normal pellet diet (NPD) or a high-fat diet (HFD) for 8 weeks to establish metabolic dysfunction, then subdivided into five groups (n=5 each) for 4 additional weeks: NPD, HFD, HFD with carbohydrate replaced by purified unprocessed BTMS (24 g/100 g diet; HFDP), HFD with modified BTMS (MHFD), and an NPD+modified BTMS control (MNPD). Outcomes assessed at days 1, 57, and 85 included body weight, fasting glycaemia, intraperitoneal glucose tolerance tests (2 g/kg), plasma/serum lipids, short-chain fatty acids, free fatty acids, glycerol, β-hydroxybutyrate, serum LBP, ileal ZO-1 and occludin by ELISA, and plasma corticosterone by HPLC. BTMS was isolated by water steeping, purified to remove protein and lipid, and its hydrolytic resistance was characterised prior to dietary incorporation.

The study used only male rats (n=5 per group), so findings may not generalise to females or to humans, and the small group sizes limit statistical power and the detection of subtle effects. The 4-week intervention window after HFD induction is relatively short; longer-term studies are needed to assess durability of gut-barrier restoration and whether benefits persist beyond the intervention. Microbiome composition was not measured, leaving the mechanistic link between resistant starch fermentation, short-chain fatty acid production, and tight-junction restoration inferential rather than demonstrated. Future work should include 16S rRNA or metagenomic profiling, histological scoring of intestinal mucosa, and dose-ranging experiments in diet-induced obese models closer to human obesity, ideally followed by a proof-of-concept human pilot.

This study directly extends the corpus theme of dietary and non-pharmacological interventions that repair intestinal barrier integrity in metabolically stressed models. It parallels [§130], which examines intermittent fasting as another non-drug strategy to counteract HFD-induced metabolic and physiological deterioration in rats, providing a useful comparison of discrete dietary manipulations targeting overlapping endpoints. The mechanistic logic — resistant starch drives colonic fermentation → elevated SCFAs → reduced gut leakiness → lower systemic endotoxaemia — also extends [§127], which similarly demonstrates that a dietary/herbal extract can restore gut barrier function by modulating the gut–liver axis and lipid metabolism. The focus on tight-junction proteins ZO-1 and occludin as readouts of barrier health parallels [§155], which evaluates Saccharomyces boulardii's effects on intestinal barrier function using comparable molecular markers. Collectively, the article enriches a growing body of evidence — also touched on by [§154] regarding FODMAP restriction in gut-function studies — showing that manipulating the fermentable carbohydrate content of the diet is a tractable lever for improving both metabolic and mucosal outcomes.

• Regulatory impact of intermittent fasting on autophagy in high fat diet induced structural and cognitive brain deteriorations in rats
  Both use HFD-fed rat models and non-pharmacological dietary timing/composition interventions to reverse metabolic syndrome features, making direct mechanistic comparison of intermittent fasting vs. resistant starch substitution informative.
• Yajieshaba extract improves alcohol‑induced liver injury by regulating hepatic lipid metabolism and gut microbiota
  Both articles show that a dietary/plant-derived intervention normalises lipid metabolism and restores gut barrier proteins (including tight junctions) via modulation of the gut–liver axis, allowing readers to compare active compounds and mechanistic pathways.
• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Saccharomyces boulardii's documented restoration of ZO-1 and occludin provides a microbial-intervention benchmark against which the prebiotic/resistant-starch mechanism reported here can be contrasted.
• AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents
  This study on Akkermansia muciniphila improving obesity and metabolic status addresses overlapping endpoints (dyslipidaemia, gut barrier integrity) in a different model, highlighting how microbiome-targeted vs. substrate-targeted strategies converge on similar outcomes.
• Mechanism of FODMAP Restriction on FGID Patients
  The FODMAP restriction study examines how altering fermentable carbohydrate intake modulates gut function in patients, offering a human-context parallel to this rat-model resistant-starch intervention and highlighting the translational gap remaining.